| Identification | Back Directory | [Name]
TD 139 | [CAS]
1450824-22-2 | [Synonyms]
TD 139
CS-2525
TD-139; TD 139
3,3'-dideoxy-3,3'-di-[4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl]-1,1'-surfanediyl-di-D-galactopyranoside
β-D-Galactopyranoside, 3-deoxy-3-[4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl]-β-D-galactopyranosyl 3-deoxy-3-[4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl]-1-thio- | [Molecular Formula]
C28H30F2N6O8S | [MDL Number]
MFCD29919388 | [MOL File]
1450824-22-2.mol | [Molecular Weight]
648.64 |
| Chemical Properties | Back Directory | [Boiling point ]
1017.2±75.0 °C(Predicted) | [density ]
1.76±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
12.33±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
TD 139 is used as a galactoside inhibitors of galectins, suitable for treating pulmonary fibrosis; such as idiopathic pulmonary fibrosis in mammals. | [in vivo]
In primary lung AECs TD139 reduces TGF-β1–induced β-catenin translocation to the nucleus, with most of the β-catenin remaining at the cell surface. TD139 blocks TGF-β1–induced β-catenin phosphorylation. A marked reduction in fibrosis and β-catenin activation accompanied by decreased galectin-3 expression is observed in the lungs of WT mice treated with TD139[1]. Pretreatment of WT C57BL/6 mice with TD139 leads to the attenuation of liver injury and milder infiltration of IFNγ- and IL-17- and -4-producing CD4(+) T cells, as well as an increase in the total number of IL-10-producing CD4(+) T cells and F4/80(+) CD206(+) alternatively activates macrophages and preventes the apoptosis of liver-infiltrating MNCs[2]. |
|
|